Quantcast

Posts related to ‘PFE’

Winners as Pfizer Loses Lipitor Patent (PFE, TEVA, MYL, WPI)

Pfizer Inc. (NYSE: PFE) has a big day ahead of it.  While it has been known for years, it is a massive date: Lipitor goes off-patent and will have generic ...
Read Full Story »

Probing for Value in Big Pharmaceutical Stocks (JNJ, PFE, AZN, BMY, MRK)

It now costs about $1 billion to get a new drug to market, or, if a company is unlucky, $1 billion to fail to get the drug to market. Like ...
Read Full Story »

Media Digest (11/21/2011) Reuters, WSJ, NYTimes, FT, Bloomberg

The supercommittee appears unlikely to settle on a deficit agreement. (Reuters) A senior Chinese official says he expects the global recession to last for some time. (Reuters) Spain’s center-right People’s ...
Read Full Story »

November Share Buybacks Already Nearing $30 Billion (ALL, AIG, CBS, FIS, PFE, RAI, SBUX, SYY, TMO, VIA, VRX, PKW)

Some companies just want to keep bringing on new share buybacks whether they work or not.  Some are to stop dilution from acquisitions or employee stock options, while others are ...
Read Full Story »

All 30 DJIA Dividend Trends into 2012, Stock by Stock (DIA, AA, AXP, T, BAC, BA, CAT, CVX, CSCO, KO, DD, XOM, GE, HD, HPQ, IBM, INTC, JNJ, JPM, KFT, MCD, MMM, MRK, MSFT, PFE, PG, TRV, UTX, VZ, WMT, DIS)

The economic choppiness is coming to a head with the age of dividend hikes. The pressure is going to remain for companies to continue returning capital to shareholders while also ...
Read Full Story »

Media Digest (11/2/2011) Reuters, WSJ

George Papandreou convinces the Greek cabinet of the virtues of a national referendum on budget cuts, but he now faces the leaders of France and Germany. (Reuters) The FBI may ...
Read Full Story »

24/7 Wall St. Closing Bell (F, GM, NBG, ALU, YHOO, PFE, HD, ADM, BBX, EXEL)

The markets are beyond jittery.  From a massively overbought market discounting a recession entirely back to a market dominated by the woes of Europe.  The Europeans cannot get their bailouts straight ...
Read Full Story »

Top 12 Earnings and Economic Events This Coming Week (ADM, DNKN, PFE, GM, F, CMCSA, KFT, QCOM, WFM, AIG, EK, LNKD, SBUX, GMCR, ALU)

Earnings season is still running strong and the economic readings keep coming out as well. As we come to the end of October, there is going to be plenty of ...
Read Full Story »

Shorts Exit Weak Shares (EK, AMR, BP, LVLT)

Short sellers moved out of stocks that have fallen recently. Perhaps they believe there will be a large rally in the market. There is little else to make the shares ...
Read Full Story »

Novartis Cuts 2,000 as Pharma Industry Continues to Falter

Novartis (NYSE: NVS) said it would cut 2,000 workers and outsource some functions to companies that will do the work for less than it can. Novartis will take a restructuring ...
Read Full Story »

R&D Spenders Get No Respect

A company can spend billions of dollars on R&D and get little respect as an innovator. Even though that is the conclusion of a new study by Booz & Co., ...
Read Full Story »

Lilly’s Drugs Closer to Edge of Patent Cliff (LLY, PFE, JNJ, BMY, SNY, MRK)

Drug maker Eli Lilly & Co. (NYSE: LLY) reported third-quarter earnings this morning, and the company did a little better than analysts expected, but worries persist that the company will ...
Read Full Story »

Expected Upside Gains for Leading Pharmaceutical Companies (JNJ, PFE, AZN, BMY, MRK)

Sales for the big pharmaceutical companies are expected to be hit by pricing pressure in Europe, a lack of urgent new on the coming flu season, lower rates of prescription ...
Read Full Story »

30-Year Auction: 12 of 30 DJIA Stocks Outyield Long Bond (T, CVX, DD, GE, INTC, JNJ, KFT, MRK, PFE, PG, TRV, VZ)

The 30-Year Treasury auction, the so-called Long Bond, had a strong participation for what is technically a 29-year and 11-month bond.  The participation rate was strong enough that this still ...
Read Full Story »

Top Analyst Upgrades & Downgrades (ALKS, AMP, BWA, CSCO, CLB, DD, GTIV, HIG, JASO, JPM, JWN, NSC, ORCL, PFE, STP, TSL, UAL)

These are some of this Wednesday's top analyst upgrades, downgrades, and initiations seen having an impact from Wall Street research calls. Alkermes, Inc. (NASDAQ: ALKS) Removed from US 1 List ...
Read Full Story »